NRSN, a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, demonstrates strong financial metrics with zero debt and low liquidity ratios relative to market capitalization. However, insufficient data on income sources leads to uncertainties in non-compliant income assessment. The company's business activities are fully permissible under Shariah principles, emphasizing preservation of life. Despite compliant ratios under AAOIFI standards, non-inclusion in major Shariah indices results in an overall NON_COMPLIANT status. Investors should monitor ongoing clinical trials and financial disclosures for potential improvements in compliance visibility.